Juno Therapeutics, Inc. (JUNO) Lifted to Outperform at Raymond James Financial, Inc.
Juno Therapeutics, Inc. (NASDAQ:JUNO) was upgraded by investment analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday. The firm presently has a $45.00 target price on the biopharmaceutical company’s stock. Raymond James Financial, Inc.’s price objective suggests a potential upside of 23.36% from the stock’s current price.
Several other analysts have also recently weighed in on JUNO. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research report on Tuesday, July 11th. Morgan Stanley lowered their price objective on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Monday, May 8th. Finally, FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.48.
Shares of Juno Therapeutics (JUNO) traded up 17.87% during trading on Tuesday, reaching $43.00. The company had a trading volume of 7,241,134 shares. The firm has a 50 day moving average price of $28.62 and a 200 day moving average price of $25.14. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $43.74. The company’s market cap is $4.51 billion.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the prior year, the company earned ($0.64) earnings per share. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. Analysts predict that Juno Therapeutics will post ($3.13) earnings per share for the current year.
In other Juno Therapeutics news, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the sale, the director now owns 788,985 shares of the company’s stock, valued at approximately $23,937,804.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Anthony B. Evnin purchased 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was purchased at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the acquisition, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The disclosure for this purchase can be found here. In the last three months, insiders sold 8,053,500 shares of company stock worth $217,594,440. Insiders own 15.26% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Broadfin Capital LLC boosted its stake in Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock valued at $7,834,000 after buying an additional 86,400 shares in the last quarter. Wasatch Advisors Inc. bought a new stake in Juno Therapeutics during the second quarter valued at approximately $19,787,000. Public Employees Retirement System of Ohio boosted its stake in Juno Therapeutics by 115.3% in the second quarter. Public Employees Retirement System of Ohio now owns 56,326 shares of the biopharmaceutical company’s stock valued at $1,684,000 after buying an additional 30,170 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Juno Therapeutics by 809,500.0% in the second quarter. Tower Research Capital LLC TRC now owns 16,192 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 16,190 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares in the last quarter. 70.76% of the stock is owned by hedge funds and other institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.